What is Recombinetics?
Recombinetics stands as a preeminent force in the domain of animal gene editing, providing sophisticated solutions that bridge the gap between biomedical research and practical agricultural applications. The company is widely recognized for its development of custom gene-edited swine models, which serve as critical assets for preclinical research, offering a more precise and ethical alternative to traditional nonhuman primate models. By integrating advanced genomic technologies, Recombinetics supports the advancement of regenerative medicine and enhances sustainability within the agricultural sector.
The organization's market position is defined by its commitment to integrity-driven innovation. By addressing the complex needs of healthcare providers and agricultural stakeholders, Recombinetics has established itself as an essential partner in the life sciences ecosystem. Its focus on improving animal health outcomes while simultaneously driving biomedical breakthroughs positions the company at the intersection of high-growth biotechnology and essential scientific infrastructure.
How much funding has Recombinetics raised?
Recombinetics has raised a total of $69.8M across 10 funding rounds:
Private Equity
$540K
Private Equity
$5.7M
Multiple Rounds
$19.3M
Debt
$7M
Private Equity
$2.1M
Series A
$34M
Debt
$350K
Debt
$766K
Private Equity (2014): $540K, investors not publicly disclosed
Private Equity (2015): $5.7M, investors not publicly disclosed
Private Equity (2016): $630K, investors not publicly disclosed
Unspecified (2016): $7.7M, investors not publicly disclosed
Private Equity (2016): $11M, investors not publicly disclosed
Debt (2017): $7M, investors not publicly disclosed
Private Equity (2017): $2.1M, investors not publicly disclosed
Series A (2018): $34M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $766K backed by PPP
Key Investors in Recombinetics
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant focused on long-term value creation within the biotechnology and life sciences sectors.
Undisclosed Investor
A strategic backer providing essential capital to facilitate the scaling of advanced gene-editing research and development.
What's next for Recombinetics?
With the recent influx of capital, Recombinetics is well-positioned to transition into a new phase of operational expansion and technological refinement. The strategic deployment of these funds will likely focus on scaling its proprietary gene-editing platforms and broadening its portfolio of research models to meet the increasing demand for high-fidelity preclinical data. As the company continues to navigate the regulatory and scientific complexities of the biotech industry, the focus will remain on enhancing its service offerings and deepening its impact on global health and agricultural productivity.
Looking ahead, the firm is expected to leverage its established market presence to forge new partnerships within the pharmaceutical and biotechnology sectors. By prioritizing long-term sustainability and scientific excellence, Recombinetics is poised to maintain its leadership status, ensuring that its gene-editing solutions remain at the forefront of the next generation of biomedical innovation.
